Search
for
Sort by
Research 151–180 of 1000+
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders
- Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches
- RAGE and Its Ligands in Melanoma
- Research Advances in Therapeutic Strategies and Drug Delivery Systems for Pathological Scars
- CXCL12 inhibits hair growth through CXCR4
- SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Glutamine Metabolism Controls Stem Cell Fate Reversibility and Long-Term Maintenance in the Hair Follicle
- Dermatite atópica em uma cadela: Caso clínico
- Aberrant inflammasome activation as a driving force of human autoimmune skin disease
- Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
- Role of the Wnt signaling pathway in keratoacanthoma
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- The Role of Exosomes Derived From Mesenchymal Stromal Cells in Dermatology
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Recent advances in the genetics of alopecia areata
- Poster Abstracts
- Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
- Epidermal growth factor, innovation and safety
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
- New therapies for alopecia areata
- Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis
- Aromatic plants as cosmeceuticals: benefits and applications for skin health
- Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review